Eli Lilly has become the latest Big Pharma to buy itself into a corner of the in-vivo CAR-T space via the acquisition of Orna for up to $2.4 billion.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Eli Lilly has become the latest Big Pharma to buy itself into a corner of the in-vivo CAR-T space via the acquisition of Orna for up to $2.4 billion.